Learn more about the science behind RepliCel
RepliCel Life Sciences (TSXV: RP) CEO: We’re Excited About This Year’s Developments
RepliCel Life Sciences Inc. (TSXV: RP) President and CEO Lee Buckler talks with SmallCapPower at the Bloom Burton Healthcare Investor Conference in Toronto about this regenerative medicine company that is focused on developing cell therapies for the treatment of aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. Find out what new developments RepliCel Life Sciences has planned for 2017 by watching our short video interview.
RepliCel Life Sciences is armed with data and aims for near-term revenue
In this interview, Lee Buckler speaks with Hannah Bernard about the company’s journey developing the basic science of autologous cell therapy into four products today. He then discusses recent data from the Phase 1 clinical trial for RCH-01, the treatment for pattern baldness, and what the safety and efficacy data means for investors. Lee also talks about other products in the portfolio, including the company’s nearest-term commercial asset, the dermal injector. Finally, Lee speaks about the goal to make 2017 the company’s last pre-revenue year, and what investors can look forward to for the rest of the year.
In-depth with Lee Buckler, CEO of RepliCel (RP.V) at ZIA TV
Lee Buckler, CEO of RepliCel is with ZIA TV to share about their produces and the problems that they are solving.
CEO, Lee Buckler, answers the questions
Our CEO, Lee Buckler, answers the questions of what statistical significance means, and why our RCH-01 Phase 1 trial, while not statistically significant, is significant nonetheless. Click Here for link to video.
Interview with Dr. Ross Davidson - RCT-01 Tendon Repair
Dr. Davidson has facilitated the recovery of numerous high profile professional athletes during his 30+ year career in sports medicine. In this interview, Dr. Davidson discusses the RCT-01 Tendon Repair trial and the significance of the results.
Market One Media Group Interviews CEO Lee Buckler on Market One Minute
Hannah Bernard interviews President & CEO Lee Buckler on Market One Minute on why our company is the ‘new breed’ of biotechnology companies. Shared from Market One Media Group Inc.’s Youtube page.
CEO Buckler interviewed at 2015 CIX Public Investor Day
President & CEO Lee Buckler speaks with Mark Thorborn at the Canadian Innovative Exchange (CIX) 2015 Public Investor Day in Toronto, Ontario on RepliCel Life Sciences. Video shared from smallcappower.com
RepliCel Talks with Spencer Kobren of TheBaldTruth.com
VP Lee Buckler talks with Spencer Kobren of TheBaldTruth.com on where RepliCel is at with its RCH-01 pattern baldness clinical trial.
RepliCel Presents at Stem Cell Meeting on the Mesa 2015
Vice President, Lee Buckler gives a presentation on RepliCel’s product pipeline and upcoming milestones at Stem Cell Meeting on the Mesa 2015 in La Jolla, California this October.
Shiseido Talks RepliCel Technology - Part 1
Shiseido Company Ltd. is featured in a network special on Science ZERO Japan, talking about the science behind RepliCel’s RCH-01 Hair Technology, and their own upcoming clinical trial in Japan.
Please note: English subtitles have been added.
Shiseido Talks RepliCel Technology - Part 2
Part 2 – Shiseido Company Ltd. is featured in a network special on Science ZERO Japan, talking about the science behind RepliCel’s RCH-01 Hair Technology, and their own upcoming clinical trial in Japan.
Please note: English subtitles have been added.
Interview Featured on BNN & Financial Post
Our VP Business & Corporate Development, Lee Buckler, was interviewed by Deborah Hope for Market One Minute. This 3-minute company overview can be viewed in the ‘Business Trends’ section on Financial Post’s website and on BNN (Business News Network).
Learn About RCT-01 Chronic Achilles Tendinosis Treatment
RepliCel Life Sciences is developing an autologous cell-based product for the treatment of chronic Achilles tendinosis. This treatment has the potential to restore a patient’s chronic tendinosis to a completely healed state.
2014 BioProcess International Awards
RepliCel’s VP of Business & Corporate Development Lee Buckler, accepts his Cell Therapy Industry Champion Award at this year’s BioProcess International Awards.
RepliCel CEO David Hall is Interviewed by Stuart Varney on Fox Business News
Find out how RepliCel’s recent research developments can help cure tendinosis. “We take a punch biopsy from the back of the scalp and from hair follicles, we isolate a fibroblast cell, replicate it into the millions and deliver it directly into the wound, in this case, chronic tendinosis,” says Hall.
“I’m going to go through this again just for the benefit of myself and our viewers,” says Varney. “You take a biopsy from the back of a neck, you take cells out, you put them in a lab, you grow them by the million, you take them, you put them right where the tendinosis is really hurting…and it jump starts the healing process to complete.”
Learn About RCT-01 Chronic Tendinosis Treatment
David Hall discusses RepliCel’s new fibroblast technology to treat sports injuries.
Learn About RCH-01 Androgenic Alopecia Treatment
RepliCel Life Sciences is developing an autologous cell-based procedure for the treatment of androgenic alopecia (pattern baldness) and general hair loss in men and women. The procedure has the potential to become the first minimally invasive solution for hair loss.
Learn About the Company
Meet David Hall — CEO, President & Director of RepliCel, and Dr. Rolf Hoffmann, MD — Chief Medical Officer & Director at RepliCel. The two experts discuss their vision for RepliCel.
Learn About the Science
Dr. Rolf Hoffmann and David Hall discuss RepliCel’s autologous cell implantation technology using dermal sheath cup cells.